EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gut Dysbiosis as a Shared Mechanism in Obesity and Hypertension: Exploring a Promising Therapeutic Avenue

Andrej Belančić iD, Almir Fajkić iD, Yusuf Ziya Sener, Ana Jelaković, Lejla Alić, Elvira Meni Maria Gkrinia iD, Donatella Verbanac, Bojan Jelaković

Endocrinology, Diabetes & Metabolism · 2026-05 · 9 (3)

DOI: 10.1002/edm2.70159 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrinology, Diabetes & Metabolism, online erschienen am 28.03.2026. Verfasst von Andrej Belančić und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia. Hauptthemen laut MEDLINE: Dysbiosis, Hypertension, Obesity, Gastrointestinal Microbiome. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 166 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Obesity and hypertension are interrelated global health challenges sharing common pathophysiological mechanisms, including insulin resistance, chronic inflammation and neurohormonal dysregulation. Emerging evidence highlights the gut microbiome as a crucial mediator in this interplay, influencing intestinal barrier integrity, systemic inflammation and metabolic homeostasis.

Methods

In this narrative review, we critically examine the interplay between obesity‐induced hypertension and the gut microbiome, evaluating current evidence, therapeutic implications and future research priorities.

Results

Obesity‐associated gut dysbiosis disrupts the intestinal epithelial barrier, increasing translocation of bacterial products like lipopolysaccharides into circulation, promoting systemic inflammation that exacerbates insulin resistance, adipose dysfunction and hypertension. Current treatments targeting obesity, from lifestyle modification to bariatric surgery, show beneficial effects on blood pressure, but microbiome‐targeted interventions are an evolving therapeutic frontier. Prebiotics, probiotics, synbiotics and faecal microbiota transplantation have demonstrated potential antihypertensive effects in preclinical and clinical studies, although findings are heterogeneous and require confirmation in larger randomised trials. Methodological challenges remain, including the need for advanced microbial sampling techniques beyond faecal analysis to fully capture disease‐relevant microbiota alterations.

Conclusion

This review synthesises current knowledge on gut microbiome involvement in obesity‐induced hypertension, evaluates microbiome‐based therapeutic strategies and identifies critical research gaps to guide future investigations aimed at mitigating the dual pandemics of obesity and hypertension.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DysbiosisHypertensionObesityGastrointestinal MicrobiomeHumansAnimalsPrebioticsProbioticsIntestinal Barrier FunctionFecal Microbiota Transplantation

Stichwörter der Autor:innen

gut microbiomeintestinal barrier dysfunctionmetabolic syndromemicrobiome‐targeted therapyobesity‐induced hypertension

Substanzen

Prebiotics

Autor:innen und Institutionen

  • Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia.
  • Department of Pathophysiology, Faculty of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
  • Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Department of Nephrology, Arterial Hypertension, Dialysis and Transplantation, University Hospital Center Zagreb, Zagreb, Croatia.
  • University of Rijeka, Faculty of Medicine, Rijeka, Croatia.
  • Department of Medical Biochemistry, Faculty of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.

ORCID-Profile: Andrej Belančić, Almir Fajkić, Elvira Meni Maria Gkrinia

Zitieren

APA

Belančić, A., Fajkić, A., Sener, Y. Z., Jelaković, A., Alić, L., Gkrinia, E. M. M., Verbanac, D., & Jelaković, B. (2026). Gut Dysbiosis as a Shared Mechanism in Obesity and Hypertension: Exploring a Promising Therapeutic Avenue. Endocrinology, Diabetes & Metabolism, 9(3). https://doi.org/10.1002/edm2.70159

Vancouver

Belančić A, Fajkić A, Sener YZ, Jelaković A, Alić L, Gkrinia EMM, et al. Gut Dysbiosis as a Shared Mechanism in Obesity and Hypertension: Exploring a Promising Therapeutic Avenue. Endocrinology, Diabetes & Metabolism. 2026;9(3). doi:10.1002/edm2.70159

BibTeX
@article{Belani2026,
  author = {Belančić, Andrej and Fajkić, Almir and Sener, Yusuf Ziya and Jelaković, Ana and Alić, Lejla and Gkrinia, Elvira Meni Maria and Verbanac, Donatella and Jelaković, Bojan},
  title = {Gut Dysbiosis as a Shared Mechanism in Obesity and Hypertension: Exploring a Promising Therapeutic Avenue},
  journal = {Endocrinology, Diabetes & Metabolism},
  year = {2026},
  volume = {9},
  number = {3},
  doi = {10.1002/edm2.70159}
}
Kostenlos starten →